Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q1 2021 · 10-Q
Revenue—
Net Income-$14.46M-$14.46MN/M vs Q1 2020 EPS Diluted-$0.12-$0.12N/M vs Q1 2020 Operating Income-$14,190,935N/M Operating Cash Flow-$13,324,648N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end